EPISODE · Dec 23, 2020 · 41 MIN
GU Podcast (2020) - Sequencing Of Agents And Combination Of Treatment Options For Bladder Cancer
from AUAUniversity · host American Urological Association
At the conclusion of this activity, participants will be able to: 1. Evaluate treatment plans including the sequencing and combination of treatment options for individual patients. 2. Explain best practices in MIBC and NMIBC patient selection for various treatment options. 3. Facilitate discussions with patients and caregivers regarding their treatment options. This educational series is supported by independent educational grants from: • Astellas • AstraZeneca • Bristol Myers Squibb • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC • Merck • Pfizer, Inc • Sanofi Genzyme • UroGen Pharma, Inc. CME Available: auau.auanet.org/node/29836
What this episode covers
At the conclusion of this activity, participants will be able to: 1. Evaluate treatment plans including the sequencing and combination of treatment options for individual patients. 2. Explain best practices in MIBC and NMIBC patient selection for various treatment options. 3. Facilitate discussions with patients and caregivers regarding their treatment options. This educational series is supported by independent educational grants from: • Astellas • AstraZeneca • Bristol Myers Squibb • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC • Merck • Pfizer, Inc • Sanofi Genzyme • UroGen Pharma, Inc. CME Available: auau.auanet.org/node/29836
NOW PLAYING
GU Podcast (2020) - Sequencing Of Agents And Combination Of Treatment Options For Bladder Cancer
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.